Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$72.05 USD

72.05
623,756

+2.37 (3.40%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $72.05 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Globus Medical (GMED) Down 3.1% Since Last Earnings Report: Can It Rebound?

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down

Globus Medical's (GMED) legacy business continues to drive share growth across its U.S. spine and trauma portfolios in the third quarter.

Globus Medical (GMED) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Why Globus Medical (GMED) is Poised to Beat Earnings Estimates Again

Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Analysts Estimate Silk Road Medical (SILK) to Report a Decline in Earnings: What to Look Out for

Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

Smart Beta ETF report for XHE

Globus Medical (GMED) Gains From NuVasive Buyout, Innovation

Globus Medical (GMED) is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

GMED or ABCM: Which Is the Better Value Stock Right Now?

GMED vs. ABCM: Which Stock Is the Better Value Option?

Here's Why You Should Buy Globus Medical (GMED) Stock Now

Investors are optimistic about Globus Medical (GMED) on growing musculoskeletal devices demand and strong industry prospects.

Globus Medical (GMED) Launches NuVasive's NSO in Global Market

Globus Medical's (GMED) Precice Bone Transport is a less intrusive treatment that reduces complications for both the patient and the surgeon and is designed for various bone abnormalities.

Globus Medical (GMED) Completes NuVasive Merger Agreement

Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most comprehensive, innovative offerings.

Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip

According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies.

Here's What Key Metrics Tell Us About Globus Medical (GMED) Q2 Earnings

The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 5% and 3.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical (GMED) Gains on Innovation, Strategic Deal

Globus Medical's (GMED) Enabling technology sales improvement is driven by strong performance of its robotic and imaging system.

ITGR or GMED: Which Is the Better Value Stock Right Now?

ITGR vs. GMED: Which Stock Is the Better Value Option?

Here's Why You Should Retain Globus Medical (GMED) Stock Now

New product developments and the pending NuVasive acquisition raise optimism about the Globus Medical (GMED) stock.

Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe

Globus Medical (GMED) continues to make significant progress in launching its prone lateral patient positioning system.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.

Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod

Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.

Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips

The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.

Globus Medical (GMED) Surpasses Q1 Earnings and Revenue Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 3.92% and 8.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?